Zacks: Analysts Anticipate Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) to Announce -$0.49 EPS

Wall Street analysts expect Verrica Pharmaceuticals Inc. (NASDAQ:VRCAGet Rating) to post ($0.49) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Verrica Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.36). Verrica Pharmaceuticals reported earnings per share of ($0.35) during the same quarter last year, which suggests a negative year over year growth rate of 40%. The firm is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Verrica Pharmaceuticals will report full-year earnings of ($2.04) per share for the current fiscal year, with EPS estimates ranging from ($2.28) to ($1.79). For the next financial year, analysts anticipate that the business will post earnings of ($1.52) per share, with EPS estimates ranging from ($2.26) to ($1.05). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Verrica Pharmaceuticals.

Verrica Pharmaceuticals (NASDAQ:VRCAGet Rating) last announced its quarterly earnings results on Wednesday, March 2nd. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.13.

A number of equities analysts have weighed in on VRCA shares. Needham & Company LLC lowered their price target on Verrica Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, March 3rd. HC Wainwright restated a “buy” rating on shares of Verrica Pharmaceuticals in a report on Monday, March 7th. Zacks Investment Research upgraded Verrica Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price objective for the company in a report on Friday, May 13th. Brookline Capital Acquisition initiated coverage on Verrica Pharmaceuticals in a report on Thursday, March 10th. They set a “buy” rating and a $20.00 price objective for the company. Finally, Brookline Capital Management restated a “buy” rating on shares of Verrica Pharmaceuticals in a report on Thursday, March 10th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Verrica Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $16.89.

Several hedge funds have recently modified their holdings of VRCA. BlackRock Inc. boosted its stake in shares of Verrica Pharmaceuticals by 23.1% in the fourth quarter. BlackRock Inc. now owns 794,466 shares of the company’s stock valued at $7,278,000 after buying an additional 149,248 shares during the period. Morgan Stanley raised its position in Verrica Pharmaceuticals by 2,540.4% during the second quarter. Morgan Stanley now owns 122,065 shares of the company’s stock valued at $1,380,000 after purchasing an additional 117,442 shares in the last quarter. Millennium Management LLC raised its position in Verrica Pharmaceuticals by 466.6% during the fourth quarter. Millennium Management LLC now owns 94,220 shares of the company’s stock valued at $863,000 after purchasing an additional 77,590 shares in the last quarter. Geode Capital Management LLC raised its position in Verrica Pharmaceuticals by 11.8% during the third quarter. Geode Capital Management LLC now owns 238,069 shares of the company’s stock valued at $2,975,000 after purchasing an additional 25,089 shares in the last quarter. Finally, Bank of America Corp DE raised its position in Verrica Pharmaceuticals by 182.9% during the fourth quarter. Bank of America Corp DE now owns 28,451 shares of the company’s stock valued at $260,000 after purchasing an additional 18,393 shares in the last quarter. Institutional investors and hedge funds own 34.58% of the company’s stock.

Shares of NASDAQ VRCA opened at $5.94 on Monday. The business’s 50 day moving average price is $7.42 and its two-hundred day moving average price is $8.59. The company has a market cap of $163.46 million, a PE ratio of -3.81 and a beta of 1.96. Verrica Pharmaceuticals has a twelve month low of $5.20 and a twelve month high of $14.79.

Verrica Pharmaceuticals Company Profile (Get Rating)

Verrica Pharmaceuticals Inc, a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

Featured Stories

Get a free copy of the Zacks research report on Verrica Pharmaceuticals (VRCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.